StockNews.com upgraded shares of Myriad Genetics (NASDAQ:MYGN – Free Report) from a hold rating to a buy rating in a report ...

Ovarian cancer (OC) is the fifth most common cause of cancer-related mortality worldwide and represents the leading cause of death for gynecological malignancies. Nevertheless, over the last years, ...

The presence of biomarkers, even in small amounts, can shape the course of treatment for a patient, says Andy Guinigundo, MSN, RN, CNP, ANP-BC.

The germline BRCA (gBRCA) pre-screen programme has grown out of Owkin's ongoing collaboration with Gustave Roussy and the Centre Léon Bérard through PortrAIt, a French consortium to accelerate ...

means it can only be used as second-line maintenance therapy after platinum-based chemotherapy in patients with these cancers whose tumours carry a germline BRCA mutation – around 15% of the ...

and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic test, a tumor test that determines homologous recombination ...

Of eight Nolan brothers and sisters, two have died from cancer and three more have now been affected by it. A leading expert ...

1 In the nonmetastatic prostate cancer setting, deleterious germline BRCA2 and BRCA1 mutations have been associated with worse metastasis-free survival and overall survival in patients treated with ...

After hours: March 21 at 5:39:59 PM EDT Loading Chart for MYGN ...

*During data validation and verification for the manuscript, one patient that was originally reported as having a response in the 2021 AACR Annual Meeting presentation of this cohort was found instead ...